EXELIXIS, INC. (EXEL) — SEC Financial Statements & Analysis

EXELIXIS, INC. (EXEL) is a biological products, (no diagnostic substances) company, incorporated in DE. EXELIXIS, INC. trades on Nasdaq as: EXEL. EXELIXIS, INC. (EXEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, EXELIXIS, INC. carries a market cap of $13.65B, a P/E ratio of 15.86x, a P/B ratio of 7.40x, a P/S ratio of 5.60x, an enterprise value of $13.37B, and an EV/EBITDA multiple of 13.37x. On profitability, it posts a gross margin of 96.48%, an operating margin of 39.88%, a net margin of 35.33%, a Return on Equity (ROE) of 44.39%, a Return on Assets (ROA) of 33.28%, and a Return on Invested Capital (ROIC) of 45.82%. Per share, it reports EPS of $3.43, diluted EPS of $3.31, free cash flow per share of $4.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 9.23% year-over-year, net income growth of 42.89% year-over-year, and EPS growth of 55.30% year-over-year. On the balance sheet, it maintains a current ratio of 3.46x, a quick ratio of 3.21x, working capital of $888.89M, a debt-to-equity ratio of 0.35x, a debt ratio of 0.26, free cash flow of $1.17B (TTM), and net debt of $-281.45M. Figures sourced from SEC EDGAR.

Market Cap

$13.65B

P/E TTM

15.86x

EPS TTM

$3.43

P/B TTM

7.40x

ROE TTM

44.39%

ROA TTM

33.28%

Debt To Equity

0.35x

Free Cash Flow TTM

$1.17B

Net Revenue TTM Growth 1Y

9.23%

Data as of 2026-06-30 · Source: SEC EDGAR